Sight Sciences, Inc. SEC Filings

Sight Sciences, Inc. (SGHT)14,418 shares of common stock at a weighted average price of $7.06 per share. According to the footnotes, the sale was made to cover his tax liability arising from the vesting of restricted stock units. After this transaction, Taylor beneficially owned 170,831 shares of Sight Sciences common stock.

Sight Sciences, Inc. (SGHT)11/12/2025, he exercised stock options for 2,440 shares of common stock at $1.96 per share and an additional 710 shares at the same exercise price, all under the company’s equity incentive plan.

The same day, 3,150 shares of common stock were sold at a weighted average price of $8.01 per share, in multiple trades between $8.00 and $8.06. Following these transactions, Hayden beneficially owned 256,590 shares of common stock directly. The filing states the transactions were made under a Rule 10b5-1 trading plan tied to a marital separation agreement, and that his former spouse will receive all proceeds from the share sales.

Sight Sciences (SGHT) reported an insider equity grant. Chief Operating Officer Alison Bauerlein acquired 23,006 RSUs on November 11, 2025 under the company’s 2021 Incentive Award Plan at a stated price of $0 per unit. The award equals approximately $150,000 of common stock based on the grant-date price, with each RSU representing one share.

The RSUs vest in 16 equal quarterly installments from December 31, 2025 through September 30, 2029, contingent on continued service. Following this grant, Bauerlein beneficially owned 620,526 shares directly.

Sight Sciences (SGHT) disclosed a Form 4 for its Chief Financial Officer, reporting an equity award tied to service. On November 11, 2025, the officer acquired 15,337 shares of common stock at $0, reflecting settlement of a new grant of restricted stock units (RSUs) under the company’s 2021 Incentive Award Plan. Following the transaction, the officer beneficially owns 161,363 shares, held directly.

The RSU grant equals approximately $100,000 of common stock based on the grant-date price and vests in 16 equal quarterly installments from December 31, 2025 through September 30, 2029. Each RSU represents the right to receive one share of common stock and has no expiration date.

Sight Sciences (SGHT) reported an officer’s initial beneficial ownership on Form 3 effective 11/05/2025. The Chief Financial Officer beneficially owns 146,026 shares, including 28,252 shares of common stock and 117,774 restricted stock units subject to vesting conditions. Derivative holdings include stock options for 27,500 shares at $10.96 expiring 05/24/2031, 13,100 shares at $17.52 expiring 02/08/2032, and 14,400 shares at $9.78 expiring 03/16/2033, each with time-based monthly vesting as described.

Sight Sciences (SGHT) reported Q3 2025 results with revenue of $19.9 million, slightly lower than $20.2 million a year ago, as Surgical Glaucoma held steady and Dry Eye remained soft. Gross profit was $17.2 million while operating expenses fell to $25.1 million, narrowing the net loss to $8.2 million from $11.1 million. For the nine months, revenue was $57.0 million and net loss was $34.3 million.

Cash and cash equivalents were $92.4 million as of September 30, 2025, down from $120.4 million at year-end, reflecting operating cash outflows. Long-term debt stood at $40.1 million. The company amended its Hercules loan in September, extending the interest-only period to February 1, 2027 and increasing potential incremental tranches (subject to lender approval) while maintaining the $65 million facility.

Management executed a targeted restructuring in Q3, recording $2.8 million of charges to reduce operating expenses. Subsequent to quarter-end, two Medicare Administrative Contractors set jurisdiction-wide pricing for CPT 0563T tied to TearCare, effective retroactive to January 1, 2025. A prior $34 million jury verdict in patent litigation awaits judgment and may be affected by USPTO reexaminations.

Sight Sciences (SGHT) reported leadership changes and furnished Q3 updates. The company promoted Alison Bauerlein to Chief Operating Officer, effective November 5, 2025; she will serve as Principal Operating Officer and cease serving as CFO, Treasurer, Principal Financial Officer and Principal Accounting Officer.

James (Jim) Rodberg was promoted to Chief Financial Officer and Treasurer, also effective November 5, 2025, and will serve as Principal Financial and Accounting Officer. Bauerlein’s compensation includes a $485,000 base salary, a cash bonus target at 65% of salary, and RSUs valued at $150,000 vesting in 16 equal quarterly installments from December 31, 2025 through September 30, 2029. Rodberg’s terms include a $400,000 base salary, a 50% bonus target, and $100,000 in RSUs with the same vesting schedule.

Brenda Becker and Erica Rogers resigned from the Board effective November 4, 2025, stating no disagreement with the company. The Board size was reduced from nine to seven, and Catherine Mazzacco was reassigned to Class I with a term ending at the 2028 annual meeting. The company furnished an earnings press release and a leadership press release, and posted an investor presentation.

Sight Sciences announced that two Medicare Administrative Contractors, Novitas and FCSO, established jurisdiction-wide pricing for CPT 0563T, which describes the TearCare procedure. The Medicare fee schedule amount is $1,141.59, effective for dates of service on and after January 1, 2025, across all Novitas and FCSO jurisdictions.

The local fee schedules are active for claim processing and are expected to be posted on the Novitas and FCSO websites. TearCare claims in these areas will be payable based on individual medical necessity determinations. The regions covered by these MACs have an estimated 10.4 million total covered lives. The company also posted an investor presentation and plans to provide updated revenue and adjusted operating expenses guidance during its third quarter 2025 earnings call.

Sight Sciences, Inc. reporting person Brenton Taylor disclosed a sale of 591 shares of common stock on 10/06/2025. The sale was executed to cover the reporting person's tax liability related to the vesting of restricted stock units and occurred in multiple transactions at prices ranging from $3.32 to $3.45, with a weighted average price of $3.37. After the reported sale, the reporting person beneficially owned 185,249 shares, held directly. The form bears a signature date of 10/08/2025.